AETHLON MEDICAL INC (AEMD): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
AETHLON MEDICAL INC (AEMD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 11, 2026, Aethlon Medical, Inc. (the “Company”) entered into amendments to the employment agreements of James
How this was made
The 30-second read
Why it matters
The changes are administrative, with no alteration to severance amounts, suggesting limited market impact.
Market read
Low relevance; primarily of interest to current shareholders and potential acquirers.
What to watch
Potential future M&A activity that could trigger the change‑in‑control clause is not discussed.
Background
Aethlon Medical filed a Form 8‑K detailing amendments to executive employment agreements, a routine corporate disclosure.
Ticker impact
SEC 8‑K reports amendments to CEO/CFO and CMO employment agreements to pay severance and COBRA benefits in a lump‑sum upon a change‑in‑control termination.
minimal impact; no immediate price move expected
Compensation timing changes are administrative and rarely drive short‑term trading activity.
Market effects
None; the filing is company‑specific and does not affect the broader biotech sector.
None; limited to Aethlon Medical investors.
None
Counterpoint
If investors anticipate a pending change‑in‑control event, the lump‑sum provision could be viewed as a risk mitigant, potentially supporting the stock.
Key entities
- ExecutiveJames B. Frakes
CEO and CFO of Aethlon Medical
- ExecutiveSteven P. LaRosa, M.D.
Chief Medical Officer of Aethlon Medical
